{"id":"semaglutide-injectable-product","safety":{"commonSideEffects":[{"rate":"25–40","effect":"Nausea"},{"rate":"5–15","effect":"Vomiting"},{"rate":"20–30","effect":"Diarrhea"},{"rate":"15–25","effect":"Constipation"},{"rate":"10–20","effect":"Abdominal pain"},{"rate":"5–10","effect":"Hypoglycemia"}]},"_chembl":{"chemblId":"CHEMBL4752331","moleculeType":"Unknown","molecularWeight":"4113.64"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Semaglutide binds to and activates GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion and inhibiting glucagon release. It also acts on the central nervous system to reduce appetite and increase satiety, leading to decreased caloric intake and weight reduction. These combined effects improve glycemic control and body weight management in patients with type 2 diabetes and obesity.","oneSentence":"Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, reduce appetite, and promote weight loss.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:07:18.777Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Chronic weight management in adults with obesity or overweight with weight-related comorbidities"}]},"trialDetails":[{"nctId":"NCT07446998","phase":"PHASE2","title":"Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss","status":"RECRUITING","sponsor":"Veru Inc.","startDate":"2026-03","conditions":"Obesity & Overweight, Mobility Disability, HOMA-IR","enrollment":200},{"nctId":"NCT07485062","phase":"PHASE4","title":"Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2026-05-01","conditions":"Type 2 Diabetes, Cognitive Decline in Older Adults","enrollment":164},{"nctId":"NCT07227948","phase":"PHASE2","title":"Repurposing Semaglutide for the Treatment of Cocaine Use Disorder","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2026-01-15","conditions":"Cocaine Use Disorder","enrollment":75},{"nctId":"NCT05254314","phase":"PHASE2","title":"Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-10-11","conditions":"Asthma","enrollment":100},{"nctId":"NCT04019197","phase":"PHASE2","title":"Effects of Semaglutide in HIV-Associated Lipohypertrophy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Case Western Reserve University","startDate":"2019-05-16","conditions":"HIV/AIDS, Lipohypertrophy, Obesity","enrollment":108},{"nctId":"NCT06027567","phase":"PHASE4","title":"The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure","status":"COMPLETED","sponsor":"Rigmor Højland Jensen","startDate":"2022-09-02","conditions":"Idiopathic Intracranial Hypertension, Intracranial Pressure, Obesity","enrollment":38},{"nctId":"NCT07357766","phase":"PHASE3","title":"A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-06-22","conditions":"Overweight, Obesity","enrollment":1400},{"nctId":"NCT07357740","phase":"PHASE2","title":"A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-08-27","conditions":"Diabetes Mellitus, Type 2","enrollment":400},{"nctId":"NCT07430059","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant","status":"NOT_YET_RECRUITING","sponsor":"Vivani Medical, Inc","startDate":"2026-04","conditions":"Obesity & Overweight","enrollment":20},{"nctId":"NCT07280403","phase":"NA","title":"Effect of a Low-carbohydrate Diet on Weight Loss in People Using the Injectable GLP-1 Agonist Semaglutide for Weight Loss","status":"COMPLETED","sponsor":"INQUIS Clinical Research","startDate":"2024-09-12","conditions":"Weight Loss","enrollment":60},{"nctId":"NCT07136714","phase":"PHASE4","title":"Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity","status":"RECRUITING","sponsor":"Nordsjaellands Hospital","startDate":"2025-09-11","conditions":"Major Depressive Disorder","enrollment":116},{"nctId":"NCT05788965","phase":"PHASE2, PHASE3","title":"Semaglutide in CFRD","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2023-10-16","conditions":"Cystic Fibrosis, Cystic Fibrosis-related Diabetes","enrollment":8},{"nctId":"NCT06852391","phase":"PHASE4","title":"JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-06-18","conditions":"Obesity (Disorder)","enrollment":74},{"nctId":"NCT06577090","phase":"PHASE2","title":"Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo","status":"ACTIVE_NOT_RECRUITING","sponsor":"Skye Bioscience, Inc.","startDate":"2024-08-22","conditions":"Obesity","enrollment":136},{"nctId":"NCT05579249","phase":"PHASE4","title":"A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-01-19","conditions":"Obesity","enrollment":500},{"nctId":"NCT05829460","phase":"PHASE2","title":"Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2025-03-12","conditions":"Endometrial Hyperplasia","enrollment":""},{"nctId":"NCT06575738","phase":"PHASE1","title":"Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-10-11","conditions":"Obesity, Adolescent Obesity, Body-Weight Trajectory","enrollment":40},{"nctId":"NCT05443191","phase":"","title":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Finland, as Part of Local Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-10-20","conditions":"Diabetes Mellitus, Type 2","enrollment":50},{"nctId":"NCT06507475","phase":"","title":"Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-09-07","conditions":"Diabetes Mellitus, Type 2","enrollment":209},{"nctId":"NCT06954090","phase":"PHASE4","title":"Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study","status":"ENROLLING_BY_INVITATION","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2025-11-20","conditions":"Type 2 DM, Type 2 DM /Diabetic Nephropathy, Albuminuria","enrollment":50},{"nctId":"NCT06468748","phase":"PHASE4","title":"The Effects of Semaglutide on Body Composition and Performance in Military Personnel","status":"WITHDRAWN","sponsor":"United States Army Research Institute of Environmental Medicine","startDate":"2024-08-01","conditions":"Obesity","enrollment":""},{"nctId":"NCT07281196","phase":"","title":"Semaglutide Effects on Sleep Apnea in Patients With Type 2 Diabetes/Obesity and Comorbid Obstructive Sleep Apnea","status":"RECRUITING","sponsor":"Shanghai Fengxian District Central Hospital","startDate":"2025-01-01","conditions":"Sleep Apnea Syndrome (OSAS)","enrollment":15},{"nctId":"NCT05478252","phase":"PHASE3","title":"A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-08-03","conditions":"Diabetes Mellitus, Type 2","enrollment":388},{"nctId":"NCT04559815","phase":"","title":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-10-21","conditions":"Diabetes Mellitus, Type 2","enrollment":194},{"nctId":"NCT06706284","phase":"PHASE4","title":"Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes","status":"RECRUITING","sponsor":"Marzieh Salehi","startDate":"2025-04-11","conditions":"Spinal Cord Injuries, Type 2 Diabetes","enrollment":50},{"nctId":"NCT07154238","phase":"","title":"Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.","status":"ENROLLING_BY_INVITATION","sponsor":"Novo Nordisk A/S","startDate":"2025-09-26","conditions":"Obesity","enrollment":2546},{"nctId":"NCT05016882","phase":"PHASE2","title":"Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-08-31","conditions":"Non-alcoholic Steatohepatitis","enrollment":698},{"nctId":"NCT06659744","phase":"","title":"Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare Claims","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2024-10-24","conditions":"Diabetes Mellitus, Type 2","enrollment":158310},{"nctId":"NCT05443568","phase":"","title":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-03-09","conditions":"Diabetes Mellitus, Type 2","enrollment":155},{"nctId":"NCT05443334","phase":"","title":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-07-28","conditions":"Diabetes Mellitus, Type 2","enrollment":465},{"nctId":"NCT04601740","phase":"","title":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-11-17","conditions":"Diabetes Mellitus, Type 2","enrollment":145},{"nctId":"NCT04601753","phase":"","title":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-11-12","conditions":"Diabetes Mellitus, Type 2","enrollment":194},{"nctId":"NCT04537637","phase":"","title":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-08-28","conditions":"Diabetes Mellitus, Type 2","enrollment":99},{"nctId":"NCT04862923","phase":"","title":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-05-12","conditions":"Diabetes Mellitus, Type 2","enrollment":336},{"nctId":"NCT05316662","phase":"","title":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-04-06","conditions":"Diabetes Mellitus, Type 2","enrollment":187},{"nctId":"NCT04878393","phase":"","title":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Japan, as Part of Local Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-04-30","conditions":"Diabetes Mellitus, Type 2","enrollment":650},{"nctId":"NCT05670379","phase":"PHASE1","title":"Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant","status":"COMPLETED","sponsor":"Vivani Medical, Inc","startDate":"2024-12-20","conditions":"Overweight and Obesity, Type2diabetes","enrollment":24},{"nctId":"NCT06500429","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist","status":"COMPLETED","sponsor":"Neurogastrx, Inc.","startDate":"2024-06-24","conditions":"Overweight and Obesity, Healthy","enrollment":120},{"nctId":"NCT05819853","phase":"PHASE3","title":"Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-11-03","conditions":"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Obese","enrollment":80},{"nctId":"NCT06716307","phase":"PHASE1","title":"A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-12-02","conditions":"Obesity","enrollment":18},{"nctId":"NCT06374875","phase":"PHASE4","title":"Fibrosis Lessens After Metabolic Surgery","status":"RECRUITING","sponsor":"Ali Aminian","startDate":"2024-07-11","conditions":"Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH)","enrollment":120},{"nctId":"NCT05895643","phase":"PHASE2","title":"Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?","status":"COMPLETED","sponsor":"Psychiatric Centre Rigshospitalet","startDate":"2023-06-13","conditions":"Alcohol Abuse, Alcohol Addiction, Alcohol Dependence","enrollment":108},{"nctId":"NCT06118008","phase":"PHASE2","title":"A Study of HS-20094 in T2DM Participants","status":"COMPLETED","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2023-05-31","conditions":"Type 2 Diabetes","enrollment":54},{"nctId":"NCT06161844","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-02-23","conditions":"Type 2 Diabetes Mellitus","enrollment":506},{"nctId":"NCT07030621","phase":"PHASE3","title":"Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-07-01","conditions":"Acute Ischemic Stroke","enrollment":436},{"nctId":"NCT07021937","phase":"PHASE3","title":"Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-05-01","conditions":"Obesity/Therapy","enrollment":120},{"nctId":"NCT06974825","phase":"PHASE2","title":"A Study of BGM0504 in Chinese Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"BrightGene Bio-Medical Technology Co., Ltd.","startDate":"2023-08-30","conditions":"Type 2 Diabetes","enrollment":67},{"nctId":"NCT05419726","phase":"","title":"Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2023-02-01","conditions":"Obesity","enrollment":20},{"nctId":"NCT05786521","phase":"PHASE4","title":"Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2023-04-01","conditions":"Aging, Diabetes Mellitus, Type 2, PreDiabetes","enrollment":20},{"nctId":"NCT03899402","phase":"PHASE2, PHASE3","title":"Triple Therapy in T1DM","status":"ACTIVE_NOT_RECRUITING","sponsor":"State University of New York at Buffalo","startDate":"2019-05-01","conditions":"Type 1 Diabetes Mellitus","enrollment":78},{"nctId":"NCT06894784","phase":"PHASE3","title":"A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2025-04","conditions":"Diabetes Type 1","enrollment":36},{"nctId":"NCT05746039","phase":"PHASE1, PHASE2","title":"Feasibility of Semaglutide in Advanced Lung Disease","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2024-01-29","conditions":"Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease","enrollment":8},{"nctId":"NCT05920889","phase":"PHASE2","title":"Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2023-08-01","conditions":"Stroke, Stroke, Acute, Stroke, Ischemic","enrollment":140},{"nctId":"NCT04538352","phase":"PHASE4","title":"Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2021-01-18","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT05205928","phase":"PHASE2, PHASE3","title":"Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2022-10-02","conditions":"Type 1 Diabetes, Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT05671653","phase":"PHASE1","title":"A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range","status":"TERMINATED","sponsor":"Pfizer","startDate":"2023-01-19","conditions":"Obesity","enrollment":32},{"nctId":"NCT06738979","phase":"PHASE3","title":"A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-03","conditions":"Obesity","enrollment":408},{"nctId":"NCT06387199","phase":"PHASE2, PHASE3","title":"Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2024-12-01","conditions":"Type 1 Diabetes, Diabetes Mellitus","enrollment":26},{"nctId":"NCT04174755","phase":"NA","title":"Semaglutide's Efficacy in Achieving Weight Loss for Those With HIV","status":"RECRUITING","sponsor":"University College Dublin","startDate":"2022-06-22","conditions":"Obesity, HIV-1-infection","enrollment":80},{"nctId":"NCT05087342","phase":"PHASE3","title":"Latino Semaglutide Study","status":"COMPLETED","sponsor":"Loma Linda University","startDate":"2022-12-13","conditions":"Obesity, Obesity; Drug, Overweight or Obesity","enrollment":119},{"nctId":"NCT04892199","phase":"PHASE4","title":"Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anders Fink-Jensen, MD, DMSci","startDate":"2021-09-01","conditions":"Metabolic Disturbance, Schizophrenia, Type 2 Diabetes","enrollment":104},{"nctId":"NCT05502562","phase":"","title":"A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-02-24","conditions":"Diabetes Mellitus, Type 2","enrollment":388},{"nctId":"NCT04537624","phase":"","title":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-08-24","conditions":"Diabetes Mellitus, Type 2","enrollment":194},{"nctId":"NCT05193578","phase":"PHASE2","title":"Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes","status":"COMPLETED","sponsor":"Jan Frystyk","startDate":"2022-01-01","conditions":"Schizophrenia, Prediabetic State","enrollment":154},{"nctId":"NCT06489457","phase":"PHASE3","title":"The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2020-09-20","conditions":"Type 2 Diabetes Mellitus, Obesity, Functional Hypogonadism","enrollment":25},{"nctId":"NCT03596450","phase":"PHASE4","title":"Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-07-13","conditions":"Diabetes Mellitus, Type 2","enrollment":1278},{"nctId":"NCT06449625","phase":"PHASE2","title":"Semaglutide in Auto-HSCT","status":"NOT_YET_RECRUITING","sponsor":"Klaus Gottlob Müller","startDate":"2024-08-12","conditions":"Intestinal Mucositis, Inflammation, Chemotherapeutic Toxicity","enrollment":40},{"nctId":"NCT06423599","phase":"PHASE2, PHASE3","title":"Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure","status":"RECRUITING","sponsor":"Jens D Hove, MD,PHD","startDate":"2024-05-17","conditions":"Heart Failure With Reduced Ejection Fraction, Obesity, Weight Loss","enrollment":100},{"nctId":"NCT06422624","phase":"PHASE1","title":"A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects","status":"NOT_YET_RECRUITING","sponsor":"Bostal Drug Delivery Co., Ltd","startDate":"2024-08","conditions":"Diabetes Mellitus, Type 2","enrollment":14},{"nctId":"NCT05646199","phase":"PHASE2, PHASE3","title":"Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)","status":"NOT_YET_RECRUITING","sponsor":"University of Hull","startDate":"2025-03-01","conditions":"Polycystic Ovary Syndrome","enrollment":60},{"nctId":"NCT06354101","phase":"","title":"The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.","status":"WITHDRAWN","sponsor":"CorEvitas","startDate":"2023-07-01","conditions":"Metabolic Health","enrollment":""},{"nctId":"NCT05813249","phase":"PHASE4","title":"Semaglutide in Nonalcoholic Fatty Liver Disease","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2023-02-15","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":180},{"nctId":"NCT05766709","phase":"PHASE1","title":"A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-03-02","conditions":"Non-alcoholic Steatohepatitis","enrollment":53},{"nctId":"NCT04624672","phase":"PHASE4","title":"Treatment of GLP-1 for Diabetic Bariatric Patients","status":"TERMINATED","sponsor":"Geisinger Clinic","startDate":"2021-08-25","conditions":"Diabetes Mellitus, Type 2","enrollment":3},{"nctId":"NCT05153564","phase":"PHASE1","title":"A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-12-13","conditions":"Diabetes Mellitus, Type 2","enrollment":27},{"nctId":"NCT04885634","phase":"PHASE3","title":"Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients","status":"WITHDRAWN","sponsor":"Axel Brandes","startDate":"2022-10","conditions":"Atrial Fibrillation, Overweight and Obesity","enrollment":""},{"nctId":"NCT05950516","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Ingection in Subjects With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2023-07-10","conditions":"Type 2 Diabetes","enrollment":478},{"nctId":"NCT03292315","phase":"PHASE4","title":"Once Weekly GLP-1 in Persons With Spinal Cord Injury","status":"COMPLETED","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2018-10-16","conditions":"Spinal Cord Injuries, Insulin Resistance, Pre Diabetes","enrollment":5},{"nctId":"NCT05473286","phase":"","title":"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice","status":"WITHDRAWN","sponsor":"Novo Nordisk A/S","startDate":"2022-09-30","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT03548987","phase":"PHASE3","title":"Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-06-04","conditions":"Metabolism and Nutrition Disorder, Obesity","enrollment":902},{"nctId":"NCT04228354","phase":"PHASE1","title":"A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-01-29","conditions":"Healthy Volunteers, Overweight, Obesity","enrollment":28},{"nctId":"NCT04238962","phase":"PHASE1","title":"A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-02-03","conditions":"Overweight, Obesity","enrollment":111},{"nctId":"NCT01930188","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-12-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":1231},{"nctId":"NCT02207374","phase":"PHASE3","title":"A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-08-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":601},{"nctId":"NCT01324505","phase":"PHASE1","title":"Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":43},{"nctId":"NCT00851773","phase":"PHASE1","title":"Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-02","conditions":"Diabetes, Healthy","enrollment":84},{"nctId":"NCT00813020","phase":"PHASE1","title":"A Clinical Trial Investigating the Comparison of Three Different Concentrations of NN9535 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["semaglutide","Ozempic","Wegovy","Semaglutide plus lifestyle and cardiovascular risk factor management","Semaglutide and Lifestyle Counseling"],"phase":"marketed","status":"active","brandName":"Semaglutide Injectable Product","genericName":"Semaglutide Injectable Product","companyName":"Neurogastrx, Inc.","companyId":"neurogastrx-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, reduce appetite, and promote weight loss. Used for Type 2 diabetes mellitus, Chronic weight management in adults with obesity or overweight with weight-related comorbidities.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}